Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01997255 : Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)
PhasePhase 2
AgesMin: 2 Years Max: 18 Years
Inclusion Criteria:

- 2-18 years of age, male and female.

- Subject weights greater than or equal to 6 kg at study entry.

- Subjects clinically diagnosed with SWS, inclusive of cerebral and dermatologic
involvement. Ophthalmic involvement will be monitored if present, but is not
necessary for enrollment.

- History of epilepsy with a history of at least 4 seizures in the month prior to

- Medically refractory epilepsy defined as failure of two or more approved
antiepileptic therapies.

- Females of child-bearing potential must use highly effective contraception during the
study and for 8 weeks after stopping treatment.

- Sexually active males must use a condom during intercourse while taking study drug,
and for 8 weeks after stopping study treatment.

- Adequate bone marrow function.

- Adequate liver function.

- Adequate renal function.

- Acceptable fasting serum cholesterol and fasting triglycerides levels.

Exclusion Criteria:

- Patients currently receiving anticancer therapies or who have received anticancer
therapies within 4 weeks of the start of Everolimus (including chemotherapy,
radiation therapy, antibody based therapy, etc.).

- Known intolerance or hypersensitivity to Everolimus or other rapamycin analogs.

- Known impairment of gastrointestinal (GI) function or GI disease that may
significantly alter the absorption of oral Everolimus.

- Uncontrolled diabetes mellitus despite adequate therapy.

- Patients who have any severe and/or uncontrolled medical conditions.

- Chronic treatment with corticosteroids or other immunosuppressive agents. Topical or
inhaled corticosteroids are allowed.

- Known history of HIV seropositivity.

- Patients who have received live attenuated vaccines within 1 week of start of
Everolimus and during the study.

- Patients who have a history of another primary malignancy, with the exceptions of:
non-melanoma skin cancer, and carcinoma in situ of the cervix, uteri, or breast from
which the patient has been disease free for ?3 years.

- Patients with a history of non-compliance to medical regimens or who are considered
potentially unreliable or will not be able to complete the entire study.

- Patients who are currently part of or have participated in any clinical investigation
with an investigational drug within 1 month prior to dosing.

- Pregnant or nursing (lactating) women.
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557